Worldwide Clinical Trials

OCTOBER 14, 2024

Fortunately, advances in clinical research are providing hope for better treatments and outcomes. With the support of global networks like ours at Worldwide Clinical Trials (Worldwide), autoimmune and bone health research is accelerating, providing new solutions to patients around the world.

Research 130

Research Clinical Trials Clinical Trials Immune Response 130

pharmaphorum

SEPTEMBER 7, 2020

A trial of Russia’s Sputnik V coronavirus vaccine has shown the jab produces an immune response, although the study was too small to produce conclusive findings, particularly on safety. Preclinical and clinical studies have made it possible to provisionally approve the vaccine under the current Russian coronavirus regulations.

Immune Response 107

Immune Response Vaccination Vaccine Trials 107

Pharmaceutical Technology

OCTOBER 14, 2022

The mRNA-4157/V940 has been designed to stimulate an immune response by producing T-cell responses depending on the mutational signature of a patient's tumour.

Vaccination 289

Vaccination Vaccine Development Immune Response 289

World of DTC Marketing

DECEMBER 29, 2020

Once introduced into the human body, the protein-making machinery uses this genetic material in our cells to churn out the coronavirus “spike protein,” triggering an immune response. Another consideration is that while in traditional vaccine development, clinical trials are carried out in sequence.

Vaccination 307

Vaccination Vaccine Development Clinical Trials 307

XTalks

MAY 4, 2023

However, there are ongoing clinical trials for celiac disease to investigate potential new treatments. Some of the approaches being studied include: Enzyme therapy: Researchers are testing enzymes that may help break down gluten in the digestive system, reducing the risk of immune system activation and damage to the small intestine.

Clinical Trials 98

Clinical Trials Clinical Trials Trials Immune Response 98

World of DTC Marketing

APRIL 11, 2021

Further scientific research into the virus and recognition that it was not like influenza A, a flu virus known to cause bronchitis, would transpire over the next 30 years. . If your body develops an immune response—the goal of vaccination—there is a possibility you may test positive on some antibody tests.

Vaccination 303

Vaccination Vaccine Clinical Trials Clinical Trials 303

pharmaphorum

JANUARY 6, 2023

The cancer immunotherapies will mainly be provided in the context of clinical trials over the alliance, which extends out to 2030, but also covers supply of commercial therapies if approved in the interim. The post UK partners with BioNTech on clinical trials of mRNA cancer therapies appeared first on.

Clinical Trials 111

Clinical Trials Clinical Trials Trials Vaccination 111

Pharmaceutical Technology

JUNE 16, 2023

The developer has tested OVX836 in four completed clinical trials. In a company statement announcing the latest trial kick-off, Osivax said a recently completed separate Phase IIa trial demonstrated that the candidate in combination with QIVs had a good safety profile with no impairment of immune response by the QIVs.

Vaccination 246

Vaccination Vaccine Trials Immune Response 246

XTalks

NOVEMBER 6, 2020

Canadian clinical-stage biotech company Symvivo Corporation has developed an oral COVID-19 vaccine that entered clinical trials this week. The first healthy volunteer was dosed with the vaccine in Australia as part of the bacTRL-Spike COVID-19 Phase I clinical trial. COVID-19 Clinical Trials.

Clinical Trials 75

Clinical Trials Clinical Trials Vaccination Vaccine 75

Worldwide Clinical Trials

MARCH 12, 2024

There are several additional tumor markers illustrated below: Circulating Tumor Cells Are Hard to Detect but Reduce Patient Burden Tumor cells sometimes break away from the tumor and circulate in the bloodstream, allowing researchers to measure them as circulating tumor cells (CTCs).

Clinical Trials 182

Clinical Trials Clinical Trials Immune Response Trials 182

XTalks

OCTOBER 24, 2024

Trends in Psoriasis Research: Biologics, Biosimilars and New Therapies Recent innovations in biologics and biosimilars have transformed psoriasis care. In August 2024, Artax Biopharma completed patient recruitment for its Phase IIa trial of AX-158, exploring a new immune-modulating therapy for psoriasis.

Research 105

Research Dermatology Clinical Trials Clinical Trials 105

Worldwide Clinical Trials

JUNE 21, 2024

The 2024 ASCO Annual Meeting from the American Society of Clinical Oncology is a fantastic platform for clinical researchers to discuss the latest advancements and challenges in oncology research. Check out this webinar on navigating the landscape of oncology clinical trials.

Antibody 162

Antibody Clinical Trials Clinical Trials In-Vitro 162

Medical Xpress

JANUARY 30, 2023

A newly published paper in The Lancet shows that an experimental vaccine against Marburg virus (MARV) was safe and induced an immune response in a small, first-in-human clinical trial.

Vaccination 106

Vaccination Vaccine Immune Response Allergies 106

pharmaphorum

MAY 19, 2022

Moderna’s vaccines deliver HIV-specific antigens discovered by researchers at IAVI and Scripps Research that have already been tested in a proof-of-concept study carried out last year using an adjuvant protein vaccine approach. HVAD #HVAD2022 pic.twitter.com/KLrVRXtEAv. — Moderna (@moderna_tx) May 18, 2022.

Vaccination 145

Vaccination Vaccine Trials Immune Response 145

Pharmaceutical Technology

MAY 19, 2023

OncoResponse has secured a $13m grant from the Cancer Prevention and Research Institute of Texas (CPRIT) and raised an additional $14m in funding from investors for advancing OR502 to investigational new drug (IND) and clinical trials. It is planned to enter clinical studies this year.

Immune Response 130

Immune Response Clinical Trials Clinical Trials Antibody 130

Pharmaceutical Technology

OCTOBER 6, 2022

BioLink Life Sciences has received a contract worth $750,000 from the US Biomedical Advanced Research and Development Authority (BARDA) to develop Ramatroban for treating Covid-19 pneumonia patients in the hospital setting. Ramatroban will be analysed in a placebo-controlled, randomised Phase II/III RAMBAN-1 clinical trial.

Development 162

Development Life Science Immune Response Trials 162

Pharmaceutical Technology

MAY 10, 2023

XinThera’s therapy targeting MK2 is expected to enter clinical trials later in 2023. By adding an additional pipeline targeting oncology and inflammation diseases, the company expects that the deal will complement its existing clinical development priorities.

Immune Response 130

Immune Response DNA Clinical Trials Clinical Trials 130

pharmaphorum

FEBRUARY 25, 2021

Maryland, US-based company Altimmune is among the biotechs and research labs trying to find more convenient alternatives and believes a nasal vaccine spray that is stable at room temperature could be the answer. A nasal delivery method will also produce an immune response at the point where the virus enters the body.

Vaccination 111

Vaccination Vaccine Immune Response Trials 111

The Pharma Data

DECEMBER 23, 2020

In the context of a substantial amount of COVID-19-related research and the launch of numerous clinical trials, the French government created this steering committee to prioritize and accelerate high potential clinical trials. This Phase IIa trial follows a preliminary study conducted by Prof.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Research 52

Pharmaceutical Technology

APRIL 28, 2023

Therini Bio will use part of the funds to advance its potential first-in-class investigational antibody, THN391, into clinical trials. THN391 binds the inflammation-driving component of fibrin, known for activating the immune responses in neurodegenerative and ophthalmologic diseases.

Development 130

Development Immune Response Clinical Trials Clinical Trials 130

STAT News

DECEMBER 23, 2022

In a clinical trial, 60% of patients with follicular lymphoma treated with Lunsumio achieved a complete response. The most common side effect was an overactive immune response called cytokine release syndrome, reported by 39% of patients. Continue to STAT+ to read the full story…

FDA Approval 98

FDA Approval Immune Response Drugs Research 98

XTalks

DECEMBER 29, 2023

Reese, executive vice president of Research and Development at Amgen, in the company’s press release. Tarlatamab is an investigational drug currently undergoing clinical trials to assess its efficacy in patients with two distinct types of neuroendocrine cancer: SCLC and neuroendocrine prostate cancer (NEPC).

Clinical Trials 119

Clinical Trials Clinical Trials FDA Approval Trials 119

XTalks

DECEMBER 3, 2024

Building on this history of success, Novocure recently revealed promising Phase III results from the PANOVA-3 clinical trial, marking a significant milestone in pancreatic cancer treatment. Novocure’s broader pipeline underscores the versatility of TTFields therapy.

Trials 105

Trials Immune Response Clinical Trials Clinical Trials 105

Camargo

JULY 27, 2021

The technology of gene therapy is possible due to extensive DNA research and our resulting understanding of many diseases on the genetic level, and it encompasses several mechanisms such as introducing new genes (gene addition) and inactivating or replacing mutated genes (gene editing).

Gene Therapy 238

Gene Therapy Gene Gene Editing Genetics 238

Pharmaceutical Technology

AUGUST 5, 2022

The scientific approach of MiroBio for immune balance restoration to treat autoimmune diseases complements the inflammation research and development works of Gilead. MB272, the lead investigational antibody of MiroBio, is a selective immune inhibitory receptor B- and T-Lymphocyte Attenuator (BTLA) agonist.

Antibody 130

Antibody Immune Response Clinical Trials Clinical Trials 130

Worldwide Clinical Trials

JUNE 15, 2022

The pandemic has had a lasting impact on the ability of sites to participate in trials, particularly in the US. We’ve also seen a decrease in available research nurses, as they have had to be reassigned to COVID patients. 5 Things You Need to Know from Our Recent Gene Therapy Webinar appeared first on Worldwide Clinical Trials.

Gene Therapy 130

Gene Therapy Gene Clinical Trials Clinical Trials 130

Pfizer

FEBRUARY 16, 2023

These study participants, representing approximately half of the total recruited participants in the trial, are being discontinued following violations of Good Clinical Practice (GCP) at certain clinical trial sites run by a third-party clinical trial site operator.

Clinical Trials 76

Clinical Trials Clinical Trials Vaccination Vaccine 76

Scienmag

JANUARY 14, 2021

14, 2021) – Researchers at Baylor College of Medicine have discovered how therapeutics targeting RNA splicing can activate antiviral immune pathways in triple negative breast cancers (TNBC) to trigger tumor cell death and signal the body’s immune response. HOUSTON – (Jan.

Immune Response 41

Immune Response RNA Medicine Research 41

pharmaphorum

NOVEMBER 25, 2022

Rather than completely preventing infections, the aim would be to stimulate a memory immune response that could be quickly recalled and adapted to new pandemic viral strains. ” Hensley et al say they are currently designing human clinical trials of the vaccine candidate.

Vaccination 105

Vaccination Vaccine Research Immune Response 105

pharmaphorum

JUNE 29, 2021

Giving one dose each of AstraZeneca and Pfizer COVID-19 vaccines provides good protection against the SARS-CoV-2 virus, but may be associated with more adverse reactions, according to new clinical trial data. “There is an excellent response to a second dose, even after a 10 month delay from the first.”

Immune Response 128

Immune Response Vaccination Vaccine Antibody 128

The Pharma Data

NOVEMBER 10, 2020

Canadian biopharmaceutical company Medicago has announced that its investigational COVID-19 vaccine generated “significant antibody and cellular immune responses” after two doses in all subjects in an early-stage clinical trial. Martin Berman-Gorvine. Source link.

Immune Response 40

Immune Response Vaccination Vaccine Clinical Trials 40

XTalks

NOVEMBER 5, 2024

Proceeds from the IPO will fund preclinical and clinical development for Polyrizon’s innovative hydrogel product candidates, supporting further research and development (R&D). Trading began on the Nasdaq Capital Market under the ticker “PLRZ” on October 29, 2024. Polyrizon Ltd.

Drug Delivery 111

Drug Delivery Drugs Immune Response Allergies 111

The Pharma Data

JUNE 26, 2021

Sanofi and Translate Bio initiate Phase 1 clinical trial of mRNA influenza vaccine. Th e first clinical trial of a seasonal mRNA flu vaccine candidate is an exciting milestone in our quest for the next generation of inf lu enza vaccines. JUNE 22 , 2021.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

pharmaphorum

FEBRUARY 9, 2022

While therapeutic cancer vaccines are able to help the body identify particular proteins expressed by cancer cells and then to instigate an immune response. The spokesperson also noted that as the organisations are acting as sponsors of the trials, Vaccitech is able to redirect the funds into other projects. A broad front.

Vaccination 134

Vaccination Vaccine Clinical Trials Clinical Trials 134

XTalks

AUGUST 13, 2020

The company announced that it commenced the Phase III clinical trial to evaluate the investigational COVID-19 vaccine this week. It is also dedicated to fostering innovations in care, clinical research, health education and the support of community health. Kaiser began Phase III trials of the vaccine at the end of July.

Vaccination 89

Vaccination Vaccine Trials Clinical Trials 89

The Pharma Data

MARCH 31, 2022

A Phase 2 clinical trial evaluating various additional COVID-19 booster shots has begun enrolling adult participants in the United States. “This trial will help us understand if we can use prototype and variant vaccines alone or together to shift immune responses to cover existing and emerging COVID-19 variants.”

Clinical Trials 52

Clinical Trials Clinical Trials Trials Immune Response 52

pharmaphorum

JANUARY 5, 2022

A COVID-19 vaccine that could work against multiple variants of the coronavirus – developed by US biotech Gritstone bio – has generated encouraging immune response data in its first clinical trial.

Protein 126

Protein Vaccination Vaccine Immune Response 126